© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CAR T-Cell Therapy
Expert Addresses Role of CAR T-Cell Therapy in Solid Tumors
April 14, 2020
Prasad S. Adusumilli, MD, FACS, discusses where he sees chimeric antigen receptor T-cell therapy fitting into the treatment landscape for patients with solid tumors.
ZUMA-2 Update: KTE-X19 Induced Durable Remission in R/R Mantle Cell Lymphoma
April 03, 2020
Durable remissions were elicited with KTE-X19 in a majority of patients with relapsed or refractory mantle cell lymphoma, according to the updated results from the ZUMA-2 trial published in the New England Journal of Medicine. The treatment did, however, cause serious adverse events that were consistent with known toxicities of chimeric antigen receptor T-cell therapy.
CAR T Cells Push Forward in Solid Tumors Following Positive Results in Hematology
April 01, 2020
In an interview with Targeted Oncology, Prasad S. Adusumilli, MD, FACS, discussed the expansion of chimeric antigen receptor T-cell research in the solid tumor space and the challenges researchers will need to overcome in order to make this therapy effective for patients outside of the hematologic treatment landscape.
FDA Approval Sought for Ide-cel in Relapsed/Refractory Multiple Myeloma
March 31, 2020
A Biologics License Application has been submitted to the FDA for the investigational B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy idecabtagene vicleucel as treatment of patients with multiple myeloma who have received at least 3 prior therapies.
Managing Known CAR T-Cell Toxicities With KTE-X19
March 09, 2020
David Miklos, MD, PhD, describes the toxicity profile of KTE-X19, a chimeric antigen receptor T-cell therapy, in the ZUMA-2 trial.
Existing CAR T Cells Show Promise Even as Newer Agents Emerge in Multiple Myeloma
February 28, 2020
In an interview with Targeted Oncology at the 2020 International Congress on Hematologic Malignancies, Noopur Raje, MD, discussed emerging CAR T-cell therapies in multiple myeloma. She also explained how CAR NK cells differ from other CAR agents.
Implementing EMR in Clinical Practice for Patients Receiving CAR T-Cell Therapy
February 28, 2020
Dylan Essner explains how Epic, an electronic medical record, can be used by nurses and oncology providers who are treating patients with chimeric antigen receptor T-cell therapy.
Favorable Safety and Efficacy May Be Possible With Off-the-Shelf CAR T Cells in NHL
February 22, 2020
Use of an off-the-shelf chimeric antigen receptor T-cell product may be feasible for use in patients with relapsed/refractory B-cell malignancies for whom no other available therapies exist, according to results of a phase I trial in adult and pediatric patients that were presented at the 2020 Transplant & Cellular Therapies Meeting in Orlando, Florida.
CAR T-Cell Therapy With Liso-Cel in the Outpatient Setting Reported as Safe and Effective
February 21, 2020
Outpatient treatment with lisocabtagene maraleucel had consistent efficacy and safety with that of a previously reported clinical trial involving patients who were treated at university medical centers, according to results of 3 studies reported at the 2020 Transplantation & Cellular Therapy Meetings in Orlando, Florida.
Factors Affecting Hemopoietic Recovery in Patients Following CAR T-Cell Therapy
February 21, 2020
In an interview with Targeted Oncology at the 2020 Transplantation & Cellular Therapy Meetings, Craig Sauter, MD, discussed the retrospective real-world review of patients with hematologic malignancies who developed cytopenia post-chimeric antigen receptor T-cell therapy.